Figure 2 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2
<p>Exposure-time profile of SDX-7320 and SDX-7539 in cycle 1 (<i>n</i> = 5) in patients dosed at 49 mg/m<sup>2</sup> SDX-7320. Plasma samples were prepared from blood drawn at the indicated times postdose. The levels of SDX-7320 and the small molecule SDX-7539 were meas...
Wedi'i Gadw mewn:
| Prif Awdur: | |
|---|---|
| Awduron Eraill: | , , , , , , , , , |
| Cyhoeddwyd: |
2025
|
| Pynciau: | |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|
Byddwch y cyntaf i adael sylw!